BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

Trial failure triggers 8% BioNTech drop, 6% Moderna decline, sector-wide negative readthrough.